Binary-Toxin ADC Payload Design for Low-Antigen Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibody-drug conjugates (ADCs) face inefficiencies due to limited antigen expression on tumor cells, leading to suboptimal drug delivery and poor efficacy, which is a major reason for clinical failures.

Innovation Solution

Development of an antibody-drug conjugate capable of loading binary toxins, where MMAF and another cytotoxic drug unit are connected via a linker at the antibody's cysteine binding site, enhancing tumor cell killing efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If one toxin molecule is coupled to one target antibody (conventional ADC structure), then the ADC structure is simple and manufacturable, but the drug delivery amount to tumor cells is very low resulting in poor drug effect

Engineering Contradiction:

Improvedrug delivery amountVSAvoidADC structure complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent combines two different toxin molecules (MMAF and another cytotoxic drug unit) into a single ADC construct through a bifunctional linker, creating a binary toxin ADC. This merging approach increases the total drug payload delivered to tumor cells while maintaining a manageable structural complexity through modular design

Inventive Principle:

Principle #5Merging (Combining)

2Productivity

If the antigen expression level on tumor cells is limited, then the natural antigen distribution is maintained, but the ADC activity and drug delivery efficiency become insufficient

Engineering Contradiction:

ImproveADC activityVSAvoidantigen expression level

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent changes the drug payload parameter by incorporating binary toxins with higher total cytotoxicity, thereby increasing ADC activity even when antigen expression levels remain limited. This parameter change compensates for the insufficient antigen availability on tumor cell surfaces

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If the average DAR value is kept at ideal level (3.5-4), then the ADC maintains balanced pharmacokinetics, but the amount of drug delivered to tumor cells remains very low

Engineering Contradiction:

Improvedrug amount deliveredVSAvoiddrug effect efficiency

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent creates a composite toxin structure where two different cytotoxic agents (MMAF and another drug unit) are combined in a single payload. This composite approach delivers increased total drug amount per ADC molecule while maintaining appropriate DAR values, thereby improving both drug quantity and therapeutic effect efficiency

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12533419B2Antibody drug conjugate loaded with binary toxins and its application

Publication Date: 2026.01.27 MABPLEX INT LTD

AI summary

The present disclosure provides an antibody-drug conjugate loaded with binary toxins. By connecting MMAF with another drug unit in series at the cysteine binding site on the antibody, the two can exert a significant synergistic effect, thereby effectively improving the effect of killing tumor cells. This provides a new solution for the development of high-efficiency and low-toxic ADCs.